广发港股创新药ETF联接(QDII)A(019670)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-448,381,830.96 |
-330,209,869.41 |
107,742,528.90 |
963,259.57 |
| 利息合计 |
661,404.65 |
944,070.41 |
137,353.73 |
42,073.38 |
| 其中：存款利息收入 |
661,404.65 |
944,070.41 |
137,353.73 |
42,073.38 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-81,367,412.68 |
39,698,885.82 |
8,337,311.09 |
1,326,964.17 |
| 其中：股票投资收益 |
- |
- |
- |
- |
| 基金投资收益 |
-81,860,692.42 |
39,222,395.18 |
8,323,522.81 |
1,321,838.45 |
| 债券投资收益 |
493,279.74 |
476,490.64 |
13,788.28 |
5,125.72 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
- |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-369,745,744.77 |
-376,108,789.62 |
98,431,207.03 |
-457,793.50 |
| 其他收入 |
2,069,921.84 |
5,255,963.98 |
836,657.05 |
52,015.52 |
| 费用 |
4,469,818.93 |
4,568,024.24 |
448,869.42 |
274,888.97 |
| 管理人报酬 |
439,566.28 |
432,726.30 |
49,767.99 |
21,275.88 |
| 基金托管费 |
87,913.29 |
86,545.37 |
9,953.68 |
4,255.24 |
| 销售服务费 |
3,823,820.09 |
3,555,149.80 |
287,391.96 |
107,572.40 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
20,696.99 |
143,747.62 |
- |
- |
| 其中：卖出回购金融资产支出 |
20,696.99 |
143,747.62 |
- |
- |
| 其他费用 |
97,056.26 |
185,369.56 |
71,711.03 |
137,010.14 |
| 利润总额 |
-452,851,649.89 |
-334,777,893.65 |
107,293,659.48 |
688,370.60 |
微信公众号
证券之星APP
基本资料
